The long latency and low penetrance of cancer development might be explained by the ability of constitutive MAPK signaling to activate anti-oncogenic programs, most notably the p16INK4a/Rb and p19ARF/p53 pathways (Palmero et al., 1998; Lin et al., 1998). The gene discussed is CDKN2A; the disease is cancer.